{"id":"W3214960410","doi":"10.1038/s41523-021-00346-1","title":"The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group","year":2021,"lang":"en","type":"review","venue":"npj Breast Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia; Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; Ontario Institute for Cancer Research","funders":"Medical Research Council; National Cancer Institute; Cancer Research UK; National Institutes of Health; National Breast Cancer Foundation; National Center for Advancing Translational Sciences; Royal Australasian College of Physicians; National Health and Medical Research Council; Breast Cancer Research Foundation","keywords":"Oncology; Immunotherapy; Breast cancer; Medicine; Tumor-infiltrating lymphocytes; Biomarker; Internal medicine; Immune checkpoint; Cancer; Clinical Oncology; Triple-negative breast cancer; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009708207,0.0004843424,0.001684066,0.0001312098,0.000139881,0.00007568312,0.0007596745,0.0004309878,0.002490636],"category_scores_gemma":[0.00003612266,0.0002715771,0.0008686139,0.0007239135,0.0004130137,0.00006848116,0.0002464785,0.0006672106,0.000005406652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001992537,"about_ca_system_score_gemma":0.002857143,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01999597,"about_ca_topic_score_gemma":0.005664071,"domain_scores_codex":[0.9965618,0.0002817235,0.00140598,0.0006670422,0.000628764,0.0004547166],"domain_scores_gemma":[0.9969824,0.0005915464,0.00117183,0.0009446556,0.0002342412,0.00007532675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009349067,0.0001265148,0.004378488,0.0004309702,0.002480616,0.0002579064,0.000111224,2.385763e-7,0.0001098503,0.000009550591,0.01018052,0.9809792],"study_design_scores_gemma":[0.001269671,0.00001557059,0.02462304,0.02415375,0.0007678755,0.003475751,0.0001428819,0.000006041384,0.000003549756,0.000006597814,0.9452745,0.0002607554],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002471339,0.9855031,0.000003562335,0.007065105,0.003688613,0.0008395672,0.001153438,0.00002458328,0.001474946],"genre_scores_gemma":[0.001009672,0.9949391,0.00002575447,0.0006028031,0.001381005,0.000868212,0.0004043365,0.00008106471,0.0006879854],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9807184,"threshold_uncertainty_score":0.9999737,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0420120292087145,"score_gpt":0.3629201689834325,"score_spread":0.320908139774718,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}